{"id":51199,"date":"2025-12-17T22:52:31","date_gmt":"2025-12-17T14:52:31","guid":{"rendered":"https:\/\/flcube.com\/?p=51199"},"modified":"2025-12-17T22:52:32","modified_gmt":"2025-12-17T14:52:32","slug":"byterna-therapeutics-raises-angel-plus-round-for-cmrna-car-t-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51199","title":{"rendered":"Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR\u2011T Pipeline"},"content":{"rendered":"\n

Byterna Therapeutics<\/strong> completed its angel plus round financing<\/strong>, exclusively invested by Efung Capital<\/strong>. Proceeds will accelerate Investigator Initiated Trial (IIT) clinical research<\/strong> on the circular mRNA (cmRNA) in vivo CAR\u2011T pipeline BR101<\/strong>. Founded in June\u202f2023, Byterna is an AI\u2011driven biopharma<\/strong> focused on cmRNA\u2011based immunotherapy, leveraging circular mRNA and targeted tLNP technologies<\/strong>.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Financing Round<\/strong><\/td>Angel Plus<\/td><\/tr>
Lead Investor<\/strong><\/td>Efung Capital (exclusive)<\/td><\/tr>
Use of Proceeds<\/strong><\/td>Accelerate IIT clinical research on cmRNA in vivo CAR\u2011T pipeline BR101<\/td><\/tr>
Company Founded<\/strong><\/td>June\u202f2023<\/td><\/tr>
Technology Focus<\/strong><\/td>AI\u2011driven circular mRNA and targeted tLNP for immunotherapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Platform & Achievements<\/h2>\n\n\n\n
Technology<\/th>Capability<\/th><\/tr><\/thead>
Seamless Circularization<\/strong><\/td>Efficient cmRNA production with high circularization rates<\/td><\/tr>
AI Sequence Design<\/strong><\/td>AI\u2011optimized sequences for stability and expression<\/td><\/tr>
Chemical Modification<\/strong><\/td>Enhanced cmRNA stability and reduced immunogenicity<\/td><\/tr>
In Vivo Targeted Delivery<\/strong><\/td>tLNP targeting T cells for in vivo CAR\u2011T generation<\/td><\/tr>
Circular mRNA CAR Design<\/strong><\/td>Proprietary design and evaluation platform<\/td><\/tr>
Platform Status<\/strong><\/td>Globally leading cmRNA in vivo CAR\u2011T development platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Pipeline & Development<\/h2>\n\n\n\n
Pipeline<\/th>Stage<\/th>Indication<\/th><\/tr><\/thead>
BR101 (cmRNA CAR\u2011T)<\/strong><\/td>IIT clinical research<\/td>Undisclosed oncology target<\/td><\/tr>
Additional Pipelines<\/strong><\/td>Multiple in vivo CAR\u2011T programs<\/td>Advanced preclinical\/IND\u2011enabling<\/td><\/tr>
Core Pipeline<\/strong><\/td>Advancing rapidly to clinical research<\/td>cmRNA CAR\u2011T platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity & Strategic Implications<\/h2>\n\n\n\n